Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Defining reality: the potential role of pharmacists in assessing the impact of progesterone receptor modulators and misoprostol in reproductive health.

Harrison DJ, Mitroka JG.

Ann Pharmacother. 2011 Jan;45(1):115-9. doi: 10.1345/aph.1P608. Epub 2010 Dec 21.

PMID:
21177418
2.

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2009 Aug;37(8):1738-48. doi: 10.1124/dmd.108.025981. Epub 2009 May 6.

PMID:
19420130
3.

Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues.

Drexler DM, Garrett TJ, Cantone JL, Diters RW, Mitroka JG, Prieto Conaway MC, Adams SP, Yost RA, Sanders M.

J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):279-88. Epub 2006 Dec 5.

PMID:
17222568
4.

In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.

Zhang D, Hanson R, Roongta V, Dischino DD, Gao Q, Sloan CP, Polson C, Keavy D, Zheng M, Mitroka J, Yeola S.

Curr Drug Metab. 2006 Dec;7(8):883-96.

PMID:
17168689
5.

Subchronic urinary bladder effects of muraglitazar in male rats.

Van Vleet TR, White MR, Sanderson TP, Cohen SM, Cano M, Arnold LL, Waites CR, Schilling BE, Mitroka J, Dominick MA.

Toxicol Sci. 2007 Mar;96(1):58-71. Epub 2006 Nov 28.

PMID:
17132713
6.

Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.

Zhang D, Wang L, Raghavan N, Zhang H, Li W, Cheng PT, Yao M, Zhang L, Zhu M, Bonacorsi S, Yeola S, Mitroka J, Hariharan N, Hosagrahara V, Chandrasena G, Shyu WC, Humphreys WG.

Drug Metab Dispos. 2007 Jan;35(1):150-67. Epub 2006 Oct 24.

PMID:
17062777
7.

Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans.

Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA.

Drug Metab Dispos. 2006 Jun;34(6):961-70. Epub 2006 Mar 15.

PMID:
16540589
9.

Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.

Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J.

Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7.

PMID:
15640381
10.

Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans.

Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, Klunk LJ.

Drug Metab Dispos. 2005 Jan;33(1):83-93. Epub 2004 Oct 22.

PMID:
15502007
11.

Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans.

Zhang D, Zhao W, Roongta VA, Mitroka JG, Klunk LJ, Zhu M.

Drug Metab Dispos. 2004 May;32(5):545-51.

PMID:
15100177
12.

Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats.

Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, Rinehart JK, Klunk L, Mitroka J.

Drug Metab Dispos. 2003 Jul;31(7):837-45.

PMID:
12814959
13.

Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans.

Iyer RA, Malhotra B, Khan S, Mitroka J, Bonacorsi S Jr, Waller SC, Rinehart JK, Kripalani K.

Drug Metab Dispos. 2003 Jan;31(1):67-75.

PMID:
12485955
14.

Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.

Malhotra BK, Iyer RA, Soucek KM, Behr D, Liao WC, Mitroka JG, Kaul S, Cohen MB, Knupp CA.

J Clin Pharmacol. 2001 Aug;41(8):833-41.

PMID:
11504270
15.

Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans.

Iyer RA, Mitroka J, Malhotra B, Bonacorsi S Jr, Waller SC, Rinehart JK, Roongta VA, Kripalani K.

Drug Metab Dispos. 2001 Jan;29(1):60-9.

PMID:
11124231
16.

Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.

Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, Barbhaiya RH.

Drug Metab Dispos. 2000 Aug;28(8):973-80.

PMID:
10901709
17.

BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs.

Grover GJ, Parham CS, Whigan DB, Mitroka JG.

J Pharmacol Exp Ther. 1996 Feb;276(2):380-7.

PMID:
8632300
18.

Cerebrospinal fluid retrieval in the conscious dog: a methods development study.

Rockar RA, Sandanaga KK, Burkett DE, Mitroka JG, Bonner RA, Weinstein MJ.

J Invest Surg. 1995 Jan-Feb;8(1):85-94.

PMID:
7734435
19.

Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.

Soike K, Huang JL, Tu JI, Stouffer B, Mitroka JG, Swerdel M, Olsen S, Bonner DP, Tuomari AV, Field AK.

J Infect Dis. 1992 Apr;165(4):732-6.

PMID:
1313071
20.

Rapid metabolic inactivation of tipredane, a structurally novel topical steroid.

Lan SJ, Scanlan LM, Mitroka J, Weinstein SH, Lutsky BN, Free CA, Wojnar RJ, Millonig RC, Migdalof BH.

J Steroid Biochem. 1988 Nov;31(5):825-34.

PMID:
3199821

Supplemental Content

Loading ...
Support Center